Showing results (31-40 of 39) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Cancer Chemotherapy and Pharmacology|July 10, 2021
Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrugCho Rong Hong, Sunali Y Mehta, H D Sarath Liyanage, et al.Molecules (Basel, Switzerland)|October 27, 2020
Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic CytotoxicityChris P Guise, Maria R Abbattista, Robert F Anderson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104Adam V Patterson, Dianne M Ferry, Shelley J Edmunds, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2010
Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumorsKevin O Hicks, Bronwyn G Siim, Jagdish K Jaiswal, et al.Journal of Medicinal Chemistry|December 19, 2017
Next-Generation Hypoxic Cell Radiosensitizers: Nitroimidazole AlkylsulfonamidesMuriel Bonnet, Cho Rong Hong, Way Wua Wong, et al.Frontiers in Pharmacology|August 30, 2017
Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in MiceYongchuan Gu, Tony T-A Chang, Jingli Wang, et al.Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3Maria R Abbattista, Amir Ashoorzadeh, Christopher P Guise, et al.Molecular Cancer Therapeutics|October 9, 2021
Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506Alexander M A van der Wiel, Victoria Jackson-Patel, Raymon Niemans, et al.JCI Insight|August 24, 2018
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinomaStephen Mf Jamieson, Peter Tsai, Maria K Kondratyev, et al.Pageof 4